Insulin Glargine Market, By Type (Insulin Glargine) and By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028
Insulin glargine is a long-acting, synthetic version of human insulin. It belongs to a drug class called long-acting insulins. It is a form of medical insulin used to manage type I and type II diabetes. Like other types of insulin, insulin glargine is used to keep blood sugar level close to normal. It works by replacing the insulin that is produced by the body and by helping move sugar from the blood into other body tissues where it is used for the energy. Insulin glargine is FDA approved to treat adults and children with type 1 diabetes and adults with type 2 diabetes. Thus, there is an increase in demand for insulin glargine worldwide.
Market Dynamics:
Increase in prevalence of diabetes, growing geriatric population, increase in number of clinical trials, increase in research and development, and increase in awareness among people are some major factors expected to aid in the growth of the global insulin glargine market.
In January 2022, FDA announced its approval of Rezvoglar (insulin glargine-aglr), a new long-acting basal insulin, for adults and children with type 1 diabetes and adults with type 2 diabetes. Rezvoglar was approved as a biosimilar to Sanofi’s Lantus (insulin glargine).
In December 2021, FDA approved a second insulin glargine biosimilar, an Eli Lilly product called Rezvoglar, which references Lantus.
In June 2020, Biocon and Mylan got the U.S. food and drug administration nod to launch for its insulin glargine injection in vial and pre-filled pen presentations, to control high blood sugar in adults with type 2 diabetes and adult and pediatric patients with type 1 diabetes.
Key features of the study:
- This report provides in-depth analysis of the global insulin glargine market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022–2028), considering 2021 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global insulin glargine market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Julphar, Biocon, Eli Lilly, Sanofi Aventis, and Novo Nordisk AS, among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global insulin glargine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global insulin glargine market.
- Global Insulin Glargine Market By Type:
- Insulin Glargine
- Global Insulin Glargine Market By Geography:
- North America
- Europe
- Asia-Pacific
- Middle East and Africa
- South America
- Company Profiles:
- Julphar
- Biocon
- Eli Lilly
- Sanofi Aventis
- Novo Nordisk AS
Table of Contents: 1. Research Objectives and Assumptions o Research Objectives o Assumptions o Abbreviations 2. Market Purview o Report Description Market Definition and Scope o Executive Summary Market Snapshot, By Type Market Snapshot, By Geography o Coherent Opportunity Map (COM) 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics Increasing prevalence of diabetes worldwide High cost of insulin glargine Increase in awareness about diabetes management o Impact Analysis o Key Highlights o Regulatory Scenario o Product launch/Approvals o PEST Analysis o PORTER’s Analysis o Merger and Acquisition Scenario 4. Global Insulin Glargine Market– Impact of Coronavirus (COVID-19) Pandemic o COVID-19 Epidemiology o Supply Side and Demand Side Analysis o Economic Impact 5. Global Insulin Glargine Market, By Type, 2017-2028, (US$ Mn) o Introduction Market Share Analysis, 2022 and 2028 (%) Y-o-Y Growth Analysis, 2017 – 2028 Segment Trends o Insulin Glargine Introduction Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn) 6. Global Insulin Glargine Market, By Geography, 2017-2028, (US$ Mn) o Introduction Market Share Analysis, 2022 and 2028 (%) Y-o-Y Growth Analysis, 2017 – 2028 Segment Trends o North America Introduction Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn) Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn) o Europe Introduction Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn) Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn) o Asia Pacific Introduction Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn) Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn) o Latin America Introduction Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn) Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn) o Middle East and Africa Introduction Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn) Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn) o Rest of World Introduction Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn) Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn) 7. Competitive Landscape o Julphar Company Highlights Product Portfolio Key Developments Financial Performance Strategies o Biocon Company Highlights Product Portfolio Key Developments Financial Performance Strategies o Eli Lilly Company Highlights Product Portfolio Key Developments Financial Performance Strategies o Sanofi Aventis Company Highlights Product Portfolio Key Developments Financial Performance Strategies o Novo Nordisk AS Company Highlights Product Portfolio Key Developments Financial Performance Strategies o Analyst Views 8. Section o Research Methodology o About us *Browse 24 market data tables and 28 figures on "Global Insulin Glargine Market” –forecast to 2028
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook